Literature DB >> 24674031

Developing a national radiation oncology registry: From acorns to oaks.

Jatinder R Palta1, Jason A Efstathiou2, Justin E Bekelman3, Sasa Mutic4, Carl R Bogardus5, Todd R McNutt6, Peter E Gabriel3, Colleen A Lawton7, Anthony L Zietman2, Christopher M Rose8.   

Abstract

PURPOSE: The National Radiation Oncology Registry (NROR) is a collaborative initiative of the Radiation Oncology Institute and the American Society of Radiation Oncology, with input and guidance from other major stakeholders in oncology. The overarching mission of the NROR is to improve the care of cancer patients by capturing reliable information on treatment delivery and health outcomes.
METHODS: The NROR will collect patient-specific radiotherapy data electronically to allow for rapid comparison of the many competing treatment modalities and account for effectiveness, outcome, utilization, quality, safety, and cost. It will provide benchmark data and quality improvement tools for individual practitioners. The NROR steering committee has determined that prostate cancer provides an appropriate model to test the concept and the data capturing software in a limited number of sites. The NROR pilot project will begin with this disease-gathering treatment and outcomes data from a limited number of treatment sites across the range of practice; once feasibility is proven, it will scale up to more sites and diseases.
RESULTS: When the NROR is fully implemented, all radiotherapy facilities, along with their radiation oncologists, will be solicited to participate in it. With the broader participation of the radiation oncology community, NROR has the potential to serve as a resource for determining national patterns of care, gaps in treatment quality, comparative effectiveness, and hypothesis generation to identify new linkages between therapeutic processes and outcomes.
CONCLUSIONS: The NROR will benefit radiation oncologists and other care providers, payors, vendors, policy-makers, and, most importantly, cancer patients by capturing reliable information on population-based radiation treatment delivery.
Copyright © 2012 (c) 2010 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID: 24674031     DOI: 10.1016/j.prro.2011.06.002

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  10 in total

1.  Demonstration of a software design and statistical analysis methodology with application to patient outcomes data sets.

Authors:  Charles Mayo; Steve Conners; Christopher Warren; Robert Miller; Laurence Court; Richard Popple
Journal:  Med Phys       Date:  2013-11       Impact factor: 4.071

2.  Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance.

Authors:  Justin E Bekelman; James A Deye; Bhadrasain Vikram; Soren M Bentzen; Deborah Bruner; Walter J Curran; James Dignam; Jason A Efstathiou; T J FitzGerald; Coen Hurkmans; Geoffrey S Ibbott; J Jack Lee; Thomas E Merchant; Jeff Michalski; Jatinder R Palta; Richard Simon; Randal K Ten Haken; Robert Timmerman; Sean Tunis; C Norman Coleman; James Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-15       Impact factor: 7.038

3.  Technology for Innovation in Radiation Oncology.

Authors:  Indrin J Chetty; Mary K Martel; David A Jaffray; Stanley H Benedict; Stephen M Hahn; Ross Berbeco; James Deye; Robert Jeraj; Brian Kavanagh; Sunil Krishnan; Nancy Lee; Daniel A Low; David Mankoff; Lawrence B Marks; Daniel Ollendorf; Harald Paganetti; Brian Ross; Ramon Alfredo C Siochi; Robert D Timmerman; John W Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-11       Impact factor: 7.038

4.  Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries.

Authors:  Gary V Walker; Sharon H Giordano; Melanie Williams; Jing Jiang; Jiangong Niu; Jill MacKinnon; Patricia Anderson; Brad Wohler; Amber H Sinclair; Francis P Boscoe; Maria J Schymura; Thomas A Buchholz; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-07-15       Impact factor: 7.038

Review 5.  Considerations for observational research using large data sets in radiation oncology.

Authors:  Reshma Jagsi; Justin E Bekelman; Aileen Chen; Ronald C Chen; Karen Hoffman; Ya-Chen Tina Shih; Benjamin D Smith; James B Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-01       Impact factor: 7.038

6.  Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.

Authors:  Jason A Efstathiou; Deborah S Nassif; Todd R McNutt; C Bob Bogardus; Walter Bosch; Jeffrey Carlin; Ronald C Chen; Henry Chou; Dave Eggert; Benedick A Fraass; Joel Goldwein; Karen E Hoffman; Ken Hotz; Margie Hunt; Marc Kessler; Colleen A F Lawton; Charles Mayo; Jeff M Michalski; Sasa Mutic; Louis Potters; Christopher M Rose; Howard M Sandler; Gregory Sharp; Wolfgang Tomé; Phuoc T Tran; Terry Wall; Anthony L Zietman; Peter E Gabriel; Justin E Bekelman
Journal:  J Oncol Pract       Date:  2013-05       Impact factor: 3.840

Review 7.  The big data effort in radiation oncology: Data mining or data farming?

Authors:  Charles S Mayo; Marc L Kessler; Avraham Eisbruch; Grant Weyburne; Mary Feng; James A Hayman; Shruti Jolly; Issam El Naqa; Jean M Moran; Martha M Matuszak; Carlos J Anderson; Lynn P Holevinski; Daniel L McShan; Sue M Merkel; Sherry L Machnak; Theodore S Lawrence; Randall K Ten Haken
Journal:  Adv Radiat Oncol       Date:  2016-10-13

Review 8.  Quality indicators for radiation oncology.

Authors:  Susan V Harden; Kim-Lin Chiew; Jeremy Millar; Shalini K Vinod
Journal:  J Med Imaging Radiat Oncol       Date:  2022-03       Impact factor: 1.667

9.  Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience.

Authors:  Elizabeth Brown; Alison Cray; Annette Haworth; Sarat Chander; Robert Lin; Brindha Subramanian; Michael Ng
Journal:  J Med Radiat Sci       Date:  2015-02-12

10.  Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study.

Authors:  Jemma M Boyle; Gemma Hegarty; Christopher Frampton; Elizabeth Harvey-Jones; Joanna Dodkins; Katharina Beyer; Gincy George; Richard Sullivan; Christopher Booth; Ajay Aggarwal
Journal:  Eur J Cancer       Date:  2021-08-06       Impact factor: 9.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.